ZymeworksZYME
ZYME
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
150% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 5 (+3) [Q4]
106% more call options, than puts
Call options by funds: $547K | Put options by funds: $266K
55% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 20
17% more capital invested
Capital invested by funds: $833M [Q3] → $973M (+$140M) [Q4]
6% more funds holding
Funds holding: 162 [Q3] → 171 (+9) [Q4]
2.97% more ownership
Funds ownership: 93.48% [Q3] → 96.45% (+2.97%) [Q4]
23% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 61
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$13
12%
upside
Avg. target
$21
78%
upside
High target
$30
158%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
LifeSci Capital | 158%upside $30 | Outperform Initiated | 11 Mar 2025 |
HC Wainwright & Co. Robert Burns 18% 1-year accuracy 31 / 169 met price target | 12%upside $13 | Neutral Maintained | 10 Mar 2025 |
Citigroup Yigal Nochomovitz 16% 1-year accuracy 7 / 43 met price target | 64%upside $19 | Buy Maintained | 7 Mar 2025 |
Financial journalist opinion
Based on 9 articles about ZYME published over the past 30 days
Neutral
24/7 Wall Street
6 days ago
Insiders Make Huge Purchases of These 4 Biotech Stocks
After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have high expectations.
Neutral
GlobeNewsWire
6 days ago
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
1 week ago
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile
Positive
24/7 Wall Street
2 weeks ago
Huge Insider Buying: Victoria's Secret, Carl Icahn, and More
Despite (or perhaps because of) the volatility in the stock market and uncertainty about the economy, insiders are still scooping up shares of certain stocks.
Neutral
Zacks Investment Research
2 weeks ago
Zymeworks (ZYME) Soars 5.4%: Is Further Upside Left in the Stock?
Zymeworks (ZYME) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Negative
Benzinga
3 weeks ago
Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251
On Wednesday, Zymeworks Inc. ZYME released fourth-quarter financial results. The company reported an earnings loss of 31 cents per share, missing the consensus loss of 3 cents.
Neutral
Seeking Alpha
3 weeks ago
Zymeworks Inc. (ZYME) Q4 2024 Earnings Call Transcript
Zymeworks Inc. (NASDAQ:ZYME ) Q4 2024 Earnings Conference Call March 5, 2025 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Leone Patterson - Executive Vice President, Chief Business and Financial Officer Paul Moore - Chief Scientific Officer Kenneth Galbraith - Chair and Chief Executive Officer Conference Call Participants Stephen Willey - Stifel Yigal Nochomovitz - Citi Brian Cheng - JPMorgan Jonathan Miller - Evercore ISI Jay Olson - Oppenheimer & Co. Justin Zelin - BTIG Operator Thank you for standing by. This is the conference operator.
Negative
Zacks Investment Research
3 weeks ago
Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.20 per share a year ago.
Neutral
GlobeNewsWire
3 weeks ago
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
VANCOUVER, British Columbia, March 05, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today reported financial results for the fourth quarter and year ended December 31, 2024 and provided a summary of recent business highlights.
Neutral
GlobeNewsWire
1 month ago
Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced achievement of a $14 million cash research milestone from GSK associated with a clinical milestone.
Charts implemented using Lightweight Charts™